Brainstorm Cell Therapeutics, Inc. (BCLI) Shareholder Investigation

Shamis & Gentile, P.A. is investigating potential shareholder claims on behalf of Brainstorm Cell Therapeutics, Inc. ("Brainstorm Cell Therapeutics" or the "Company") (BCLI) against certain of its directors and officers for alleged breaches of fiduciary duties and other violations of law. Concerned shareholders are advised to contact the firm now.

On September 15, 2025, a federal court allowed key allegations in a securities fraud class action against Brainstorm Cell Therapeutics to proceed, increasing the potential for derivative claims that could benefit the Company. The surviving claims assert that Brainstorm Cell Therapeutics and certain officers and directors allegedly mischaracterized the Food and Drug Administration's views on the design of clinical trials for its ALS treatment NurOwn, inaccurately described certain clinical subgroup analyses as "pre-specified" when they were not, and distorted FDA feedback regarding a "floor effect" in clinical studies. The court also found sufficient allegations that the Company may have downplayed safety concerns raised by the FDA.

The underlying complaint further alleges that Brainstorm Cell Therapeutics' board and management seemingly failed to provide proper oversight regarding the Company's public disclosures about the regulatory process, the efficacy of its lead product, and the associated risks. When the alleged details emerged through adverse regulatory decisions and negative clinical feedback, investors reportedly suffered significant financial losses, including substantial stock price declines following key disclosures.

A shareholder derivative action seeks to recover damages on behalf of the Company and may result in corporate governance reforms designed to prevent similar misconduct in the future.

If you have held Brainstorm Cell Therapeutics (NASDAQ: BCLI) since at least September 27, 2023 you may be able to seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at absolutely no cost to you.

Shamis & Gentile, P.A. stands out as an advocate for shareholders seeking corporate accountability and governance reforms. The firm is committed to pursuing derivative actions that benefit companies and their shareholders by recovering damages and implementing meaningful corporate governance improvements. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including derivative actions, class actions and complex commercial litigation.

Attorney advertising. Prior results do not guarantee similar outcomes.